{{Drugbox
| verifiedrevid = 437134889
| IUPAC_name = ''N'',''N''-diethyl-''N'''-[(8Î±)-6-methylergolin-8-yl]urea
| image = Terguride.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|terguride}}
| pregnancy_category =  
| legal_status = Rx-only
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 37686-84-3
| ATC_prefix = G02
| ATC_suffix = CB06
| PubChem = 443951
|  ChemSpiderID = 392004
| IUPHAR_ligand = 56
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 21OJT43Q88
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01348

<!--Chemical data-->
| C=20 | H=28 | N=4 | O=1 
| molecular_weight = 340.46 g/mol
|  StdInChI = 1S/C20H28N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,11,14,16,18,21H,4-5,9-10,12H2,1-3H3,(H,22,25)/t14-,16+,18+/m0/s1
|  StdInChIKey = JOAHPSVPXZTVEP-YXJHDRRASA-N

| smiles = CCN(CC)C(=O)N[C@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)C
}}

'''Terguride''' ([[International Nonproprietary Name|INN]]), also known as '''''trans''-dihydrolisuride''', is a [[serotonin receptor]] [[antagonist]] and [[dopamine receptor]] [[agonist]] of the [[ergoline]] family. It is approved for and used in the treatment of [[hyperprolactinemia]]. Terguride is an oral, potent antagonist of 5-HT2B and 5-HT2A (serotonin) receptors.  Serotonin stimulates the proliferation of pulmonary artery smooth muscle cells, and induces fibrosis in the wall of pulmonary arteries.  Together, this causes vascular remodeling and narrowing of the pulmonary arteries.  These changes result in increased vascular resistance and PAH.  Due to the potential anti-proliferative and anti-fibrotic activity of terguride, this potential medicine could offer the hope of achieving reversal of pulmonary artery vascular remodeling and attenuation of disease progression.<ref>Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, Luitel H, Murmann K, Krompiec DR, Tretyn A, Pullamsetti SS, Weissmann N, Seeger W, Ghofrani HA, Schermuly RT. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. ''Biomed Research International''. 2015;2015:438403. doi 10.1155/2015/438403 {{PMID|25667920}}</ref>

In May 2008, terguride was granted [[orphan drug]] status for the treatment of [[pulmonary arterial hypertension]].<ref>[http://www.presseportal.ch/de/pm/100015139/100561578/ergonex_pharma_gmbh Presseportal (Swiss press portal, in German)]</ref>
In May 2010 [[Pfizer]] purchased worldwide rights for the drug.<ref>[http://www.theday.com/article/20100513/BIZ02/305139376/1044 TheDay.com 5/10/2010]</ref>

==References==
{{Reflist|2}}


{{Dopaminergics}}
{{Serotonergics}}
{{Ergolines}}

[[Category:Dopamine agonists]]
[[Category:Orphan drugs]]
[[Category:Serotonin antagonists]]
[[Category:Ureas]]


{{genito-urinary-drug-stub}}